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Abstract : 
Mutant form of H-Ras (Harvey-Ras) proteins are found in almost 10%-25% of human tumours. Mutational activation transforms it into an oncogenic 
form, which results in the loss of intrinsic GTPase function and therefore the protein is constitutively in the active, GTP-bound state and is continuously 
sending signals for cell growth and proliferation. In the present insilico study, the inhibitory effect of different flavonoid compounds on mutant H Ras 
protein p
21 has been assessed. In addition, inhibitory effect of flavonoids is compared with 3 known anticancer drugs. Upon docking, it was found that 
flavonoids such as Naringenin, Daidzein, and Hesperetin showed highest affinity (most negative ΔG), while Rutin showed no affinity towards mutant H 
Ras. The 3 clinical anticancer agents (Erlotinib, Letrozole and Exemestane) showed binding energies in the range of −1.11 to −5.51 kcal/mol which is 
comparatively lower than the flavonoids indicating efficacy of flavonoids in the treatment of cancer with little or no cytotoxicity. Our study demonstrates 
that flavonoids (particularly Naringenin, Daidzein, and Hesperetin) are the effective drugs to inhibit function of mutant H-Ras P21 protein, which in turn 
arrests the process of cell growth and proliferation of the cancer cell. 
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Background: 
Ras, a family of protooncogenes (N-Ras, H-Ras and KRas) codes for small 
proteins of 189 amino acids with 21 kDa molecular weight [1]. To be 
biologically active, RAS proteins are localised to the inner face of the 
plasma membrane, where they effectively interact with their upstream 
activators and downstream targets. The RAS gene proteins exist in two 
states: an active state, in which GTP is bound to the molecule and an 
inactive state, in which GTP is hydrolysed to GDP. In physiologic 
conditions, the active isoform initiates cell proliferation through the RAS 
dependent kinase cascade. The RAS proteins possess intrinsic GTPase 
activity, which normally leads to their inactivation and the control of cell 
growth. In tumours, a point mutation resulting in loss of the intrinsic 
GTPase activity is associated with transforming activity of the protein, 
which does not stop anymore to send the signal stimulating cell 
proliferation [2]. 
 
Mutational activation transforms Ras into an oncogenic form, which 
results in the loss of intrinsic GTPase function and therefore the protein is 
constitutively in the active, GTP-bound state and is continuously sending 
signals for cell growth [3,4]. Statistics reveal that 10–25% of all human 
malignancies in clinics are found to harbour a variety of Ras mutations 
[5,6], making Ras one of the most important targets to suppress tumour 
cell growth [7,8]. According to the recent surveys of the WHO 
(www.who.int/cancer/resources/incidences/en/), bladder cancer is rated 
within the five most common cancers in males in North America, Northern 
and Western Europe, and other developed countries. Transitional cell 
carcinoma (TCC) is a tumour that occurs mostly in the urinary bladder and 
has been linked to multiple and accumulated aberrations in oncogenes (e.g. 
H-ras mutations) and cancer-suppressor genes (e.g. p53 inactivation) [9-
11]. Mutational activation of the H-ras oncogene was first reported [12,13] 
in human T24 TCC cell line that played an essential role in urothelial 
carcinogenesis. Molecular epidemiological studies conducted within 
different geographic regions in different races and tumour stages/grades 
have revealed that up to 84% of bladder TCC carry activated HRas [14-
20].The amino acid position which corresponds to effector region on the 
H-Ras is 32-40 [21]. The selection of this effector region as a binding site 
will act as potential site for docking studies. This selection has been 
confirmed by two following experimental evidences. Ras is known to 
induce activation of c-Raf-1 and MAP kinase or extracellular signal 
regulated kinase (ERK). Such signal transducing activities are abolished by 
presence of mutations in the effector region Tyr32 - Tyr40. Mutations in 
the effector region affect neither guanine-nucleotide binding nor GTPase 
activity, so the effector region is considered to be the region that interacts 
with the target effectors of the Ras protein [21]. In second, the 
experimental results of x-ray crystallographic and nuclear magnetic 
resonance (NMR) analyses have shown that the three-dimensional 
structure of the Ras protein changed upon GDP to GTP exchange. In 
particular, the conformations of the Asp
30-Asp
38 and Gly
60-Glu
76 regions 
change significantly, and these regions are called switch-I and switch-II, 
respectively [21]. The switch I region essentially overlaps with the effector 
region. Some mutations in the switch I region of Ras have been reported to 
diminish the interaction with GAPs, Raf-1. The significant regions of Raf 
that bind to Ras protein have been identified as 80 amino acid N-terminal 
region, the so-called Ras binding domain (RBD) [21]. 
 
The objective of this work is to find a suitable drug (ligand) molecule for 
the mutated state of H-Ras protein to prevent complex formation with Raf 
protein. Antagonists of the Ras–Raf interactions that are likely to inhibit 
the Ras-stimulated signal transduction pathway are of great potential value 
to anti-cancer therapy.Flavonoids are a group of more than 4000 
polyphenolic compounds that occur naturally in foods of plant origin. 
These compounds possess a common phenylbenzopyrone structure (C6-
C3-C6), and they are categorized according to the saturation level and 
opening of the central pyran ring, mainly into flavones, flavanols, 
isoflavones, flavonols, flavanones, and flavanonols. The weight of the 
epidemiological evidence for a protective effect of flavonoids against 
cancer is impressive. A growing number of epidemiological studies 
suggest that high flavonoid intake may be correlated with a decreased risk 
of cancer [22]. This study has identified flavonoids as potential drug 
molecules and provides a way towards target-based drug discovery. 
 
Methodology: 
Softwares and data sources: 
All softwares used for this analysis are freely available for academic use. 
Table 1 provides the source of availability of data used for the study.The 
Protein Data Bank (PDB) (www.rcsb.org) is a worldwide repository for 
processing and distribution of 3D biological macromolecular structure data 
[23]. The protein structure of H-RAS P21 mutant (521P) and Ras-binding 
domain (1WXM) were downloaded from Protein Data Bank. The Drug 
Bank (http://redpoll.pharmacy.ualberta.ca/drugbank/) database [24] is a 
unique bioinformatics and cheminformatics resource that combines 
detailed drug (i.e., chemical, pharmacological and pharmaceutical) data Bioinformation  Volume 5  open access 
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with comprehensive drug target (i.e., sequence, structure, and pathway) 
information. The database contains nearly 4300 drug entries including 
>1000 FDA-approved small molecule drugs, 113 FDA-approved biotech 
(protein/peptide) drugs, 62 nutraceuticals and >3000 experimental drugs. 
Additionally, more than 6000 protein (i.e., drug target) sequences are 
linked to these drug entries. Each Drug Card entry contains more than 80 
data fields with half of the information being devoted to drug/chemical 
data and the other half devoted to drug target or protein data. All the 
flavonoid molecules and clinical anticancer drugs were downloaded from 
this database (Table 2). PyMol (version 1.2), is a Python-based 
visualization software [25]. The PDB files of proteins obtained from the 
Protein Data Bank can be visualized using PyMol. Pymol has been 
selected for the analysis of docking results. The docking experiments were 
performed using the docking software AutoDock 4.2 (The Scripps 
Research Institute, www.scripps.edu) [26], with the help AutoDockTools 
(ADT)—an accessory program that allows the user to interact with 
AutoDock from a Graphic User Interface (GUI). AutoDock is a suite of 
automated docking tools designed to predict how small molecules/ligands 
such as substrates or drug candidates, bind to a receptor/protein of known 
3D structure.  
 
Molecular docking: 
Molecular docking was performed for getting the drug-receptor binding 
energy. The detailing of the procedure is as follows. 
Preparing the ligand and macromolecule files for AutoDock The PDB files 
obtained from the World Wide Web repository are often far from perfect 
for docking study and present with potential problems like missing 
hydrogen atoms, multiple molecules, added waters and related problems. 
Using the GUI of ADT, following files were prepared:  
 
The Macromolecule fil: 
The downloaded PDB file of H Ras (PDB ID 521P) was first read in ADT, 
added waters removed and polar hydrogens were added. Kollman charges 
were added. Finally file was saved with .pdbq extension (where ‘q’ 
represent charge).  
The Ligand File: 
In a similar procedure, the ligand files were read in ADT, all hydrogens 
added, charges added and non-polar hydrogens merged and saved with 
.pdbqt extension. ADT then automatically determined the best root. The 
ligand files were then saved with .pdbqt extension (q representing charge).  
 
Preparing The Grid Parameter File : 
For the calculation of docking interaction energy, a three-dimensional box 
(grid) was created in which the protein molecule is enclosed. The grid 
volume was large enough to allow the ligand to rotate freely, even with its 
most fully extended conformation. The parameters required to create such 
a grid were stored in the Grid Parameter File with .gpf extension.  
 
Running Autogrid : 
Autogrid4 creates one map for every type of atom in the ligand. For 
example a molecule having C, N, O, H, maps will be created as 
molecule.C.map molecule.N.map, molecule.O.map, molecule.H.map. 
These are grid maps in ASCII format for readability by AutoDock. 
AutoGrid also generates corresponding output of the macromolecular file 
with the extension .glg. 
  
Preparing The Docking Parameter File: 
The docking parameter file, which instructs AutoDock about the ligand to 
move, the map files to use, and other properties defined for the ligand was 
created. AutoDock’s search methods include the Monte Carlo simulated 
annealing (SA) method, the Genetic Algorithm (GA), local search (LS) 
and the hybrid genetic algorithm with local search (GALS). The latter is 
also referred to as the Lamarckian genetic algorithm (LGA) because 
offsprings are allowed to inherit the local search adaptations of their 
parents and this was the chosen algorithm for our analysis.  
 
Running Autodock: 
Finally, AutoDock was run from the GUI of ADT and the docked ligand 
files were used for study. The dlg files were read in ADT as well as in 
PyMol to calculate the binding energies in the docked ligand–protein 
complexes.  
 
 
 
Figure 1: Mutated H-Ras-Ras Binding Domain (RDB) Complex Structure. 
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                       Figure 2: Ligand molecules docked onto H Ras (Green) in their lowest energy docked conformation. Ligands are shown in red. 
 
 
                       Figure 3: Ligand molecules in the active site of H Ras. 
 
Discussion : 
In order to find effective inhibitor(s) for mutant H-Ras, the binding energy 
of H-Ras and Raf interaction was initially predicted and it was compared 
with binding energies of the chosen ligands. The mutated H-Ras and RBD 
of Raf protein showed a minimal binding energy of +1.23 kcal/mol (Table 
3). The detailed structure of H Ras with RBD is shown in Figure 1 
Selecting effector region (residues 32-40) of H-Ras as binding site, all the 
ligands were docked to it. The binding energy of mutated H-Ras into each 
of the ligand molecules is shown in Table 3. Corresponding figures 
mentioned in Table 3 demonstrates the receptor ligand interactions 
(Figure. 2.1–2.7). 
 
The docked results showed that the flavonoids Naringenin, Daidzein, and 
Hesperetin had the highest affinity for the receptor (most negative ΔG). 
Rutin showed no affinity towards the receptor. Known anticancer agents 
(Erlotinib, Letrozole and Exemestane) showed binding energies in the 
range of −1.11 to −5.51 kcal/mol demonstrating efficacy of the flavonoids 
in the treatment of cancer with little or no cytotoxicity (Table 3). The 
ligand interactions were stronger (energetically lesser) as compared to H-
Ras-RBD interaction. 
 
The ligand molecules also suitably acted as drug molecule by their 
adherence to the properties such as Absorption, Distribution, Metabolism, 
and Excretion (ADME) as per the Lipinski's "rule of five". From the 
inspection of ligand molecules, it was observed that all the ligand 
molecules except Rutin were found to obey Lipinski’s rule-of-five (Table 
3). Rutin has more than 5 hydrogen bond donors and more than 10 
hydrogen bond acceptors. Many in vitro studies have been conducted on 
the potential anticancer activity of flavonoids in diverse cell systems. 
Hirano and co-workers examined anticancer efficacy of 28 flavonoids on 
human acute myeloid leukemia cell line HL-60, and compared differences 
between antiproliferative activity and cytotoxicity of these compounds 
with four clinical anticancer agents. Eight out of 28 flavonoids showed 
considerable suppressive effects on HL-60 cell growth with IC50s ranging 
from 10–940 ng/ml [27]. Kuntz et al. screened more than 30 flavonoids for 
their effects on cell proliferation and potential cytotoxicity in human colon 
cancer cell lines Caco-2 and HT-29. Almost all compoundds displayed Bioinformation  Volume 5  open access 
www.bioinformation.net  Issue 1  Hypothesis
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antiproliferative activity without cytotoxicity [28]. An array of 55 flavones 
having a variety of substituents was evaluated by Cushman and 
Nagarathnam for cytotoxicity in five cancer cell cultures, A-549 lung 
carcinoma, MCF-7 breast carcinoma, HT-29 colon adenocarcinoma, 
SKMEL-5 melanoma, and MLM melanoma. Fifteen out of the 55 flavone 
derivatives were significantly active against at least one of these cell 
cultures [29] In addition, seven out of the 27 examined Citrus flavonoids 
were observed to inhibit the proliferation of tumor cells, while less active 
against normal human cells [30]. 
 
Conclusion : 
The study concludes that flavonoids (particularly Naringenin, Daidzein, 
and Hesperetin) would be effective drugs in arresting the function of 
mutant H-Ras P21 protein. Further, these flavonoid molecules can be 
studied in the wet lab and incorporated into the drug development phases. 
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Supplementary material: 
 
Table 1: Source of data used for the study              
Protein or drug data  Source 
H Ras     PDB ID 521P 
aringenin    THE DRUG BANK (DB03467) 
Rutin    THE DRUG BANK (DB01698) 
Daidzein    THE DRUG BANK (DB02115) 
Letrozole    THE DRUG BANK (DB01006) 
Erlotinib    THE DRUG BANK (DB00530) 
Exemestane  THE DRUG BANK (DB00990)   
 
Table 2 : Structure of ligands used for the study  
Hesperetin 
 
 
     
Naringenin 
 
 
Daidzein 
 
 
 
Rutin 
     
 
Naringenin 
 
 
Letrozole 
 
 
Erlotinib 
 
 
Exemestane 
 
 
 
Table 3 : Binding Energy and Lipinski’s Values of Ligand Molecules with H Ras protein 
Ligand 
Molecules 
Binding Energy  
(Kcal/mol) 
Figure 
No. 
Molecular 
Formula 
Drug Molecular   
weight (g/mol) 
XLogP H-Bond 
Donors 
H-Bond 
Acceptors 
Hesperetin -4.59  2.1  C16H14O6 No  302.27  2.357  3  6 
Naringenin -5.50  2.2  C15H12O5 No  272.25  2.373  3  5 
Rutin +29.83  2.3  C27H30O16 No  610.51  -1.158  10  16 
Daidzein -4.61 2.4  C21H20O9 No  254.23  2.382  2  4 
Letrozole -2.90  2.5  C17H11N5 Yes  285.30  2.749  0  4 
Erlotinib -1.11 2.6  C22H23N3O4 Yes  397.46  3.487  1  7 
Exemestane -5.51  2.7  C20H24O2 Yes  296.40335  3.606  0  2 
RBD of Raf  +1.23  1.1  -  No  -  -  -  - 
 